6.1 C
Delhi
Friday, January 16, 2026

Tag: weight loss drugs

WHO Backs Ozempic, Mounjaro in First Obesity Treatment Guidelines

The WHO issues first guidelines endorsing GLP-1 drugs for obesity, calling for integrated care and urgent action on global access and equity.

Eli Lilly Hits $1 Trillion Valuation on Weight-Loss Drug Demand

Eli Lilly becomes first pharma firm to reach $1 trillion market cap as weight-loss drugs drive 47% stock surge and 54% revenue growth.

Novo Nordisk Cuts Wegovy Price, Plans Oral Weight-Loss Pill Launch

Novo Nordisk reduces Wegovy price to $349 monthly and prepares oral version to compete with Eli Lilly in the US weight-loss drug market.

Novo Nordisk Cuts Wegovy Price 37% in India Amid Competition

Wegovy weight-loss drug prices drop as patent expiry nears and Eli Lilly's Mounjaro dominates Indian market with 10x higher sales.

Pfizer Wins £7.7bn Bidding War for Weight-Loss Drug Firm

US pharma giant Pfizer triumphs over Novo Nordisk in dramatic takeover battle for Metsera, securing position in booming weight-loss drug market.

Pfizer Wins $10 Billion Metsera Acquisition After Beating Novo Nordisk

Pfizer secures obesity treatment specialist Metsera in $10 billion deal after intense bidding war. Board approves improved offer amid FTC regulatory concerns.

Pfizer Acquires Metsera in $10 Billion Weight-Loss Drug Deal

Pfizer wins competitive bidding against Novo Nordisk to acquire weight-loss startup Metsera in a landmark $10 billion pharmaceutical acquisition.

Novo Nordisk Cuts Forecasts Again Amid Weight-Loss Drug Competition

Ozempic maker Novo Nordisk slashes financial guidance for the fourth time as competition from Eli Lilly and copycat drugs intensifies in the weight-loss market.

Novo Nordisk Q3 Profit Falls 27%, Cuts 9,000 Jobs Amid Restructuring

Ozempic maker Novo Nordisk reports declining profits, job cuts and lowered outlook amid increasing competition in obesity drug market.